Intoxicating Hemp Just Got Its Day of Reckoning

By overhauling the definition of “hemp,” the new law effectively sweeps most hemp-derived tetrahydrocannabinol (THC) products off the board, into Schedule I status, by late 2026. If your business touches THCA, delta-8, delta-10, HHC, THCP, or any of the alphabet-soup cannabinoids mostly born in a lab rather than a plant, this matters — fast.

View the spending bill here.

What Changed? The New Definition (and the Teeth Behind It)

The law tightens the federal definition of hemp to mean Cannabis sativa L (including its derivatives) with no more than 0.3% “total tetrahydrocannabinols,” explicitly including THCA, on a dry-weight basis. That’s a decisive shift from the 2018 Farm Bill, which keyed only to delta-9 THC and created the now-famous “loophole” for intoxicating hemp derivatives. In other words, total THC is now the metric, not just delta-9.

The law also draws two hard lines that will push many popular products into Schedule I territory under federal law.

• “Intermediate hemp-derived cannabinoid products.” If a product contains cannabinoids that cannot be produced naturally by the cannabis plant or cannabinoids that are capable of being produced naturally by a cannabis plant but “were synthesized or manufactured outside the plant” and has more than 0.3% total THC (including THCA) or includes any cannabinoids with “similar effects” to THC (to be identified by the US Food and Drug Administration (FDA)), it’s out.

• “Final hemp-derived cannabinoid products.” If the final consumer product contains cannabinoids not naturally produced by the plant or cannabinoids that are capable of being produced naturally by a cannabis plant but “were synthesized or manufactured outside the plant” and has more than 0.4 milligrams combined per container of THC, THCA, or other THC-like cannabinoids (again, as determined by the FDA), it’s out.

As we have reported previously, the FDA has already flagged concerns with delta-8 THC. This framework gives the agency broad latitude to treat other “THC-adjacent” compounds the same way. The new law will take effect 365 days after enactment — November 12, 2026 — leaving a narrow runway for businesses and states to adjust to this new reality.

Why This Is Different? Closing the Loophole for Real

For years, the market leaned on two pillars.

1. The 2018 Farm Bill’s delta-9-only definition.

2. A chemistry set’s worth of conversions from cannabidiol (CBD) into intoxicating compounds.

Congress just knocked out both. By counting THCA toward total THC and by sidelining cannabinoids that don’t occur naturally in the plant in commercially viable quantities, the law directly targets the chemistry-driven business model that powered the sector’s explosive growth. It also punts the “similar effects” determination to the FDA, inviting a wider circle of prohibition as the science evolves.

The Real-World Consequences: Commerce, Carriers, and Cash

This is not just a definitional tweak — it is a market reset. On the ground, expect changes to move along federal chokepoints long before the effective date.

• Interstate Commerce and Shipping: Common carriers and fulfillment centers are likely to tighten policies quickly. If your business relies on national logistics to move intoxicating hemp goods, assume those lanes narrow or close, similar to how cannabis products are treated.

• Payments and Banking: Financial institutions and processors tend to de-risk ahead of enforcement. Expect stricter underwriting, higher fees, or outright offboarding for SKUs that fall under the new exclusions. While it is unknown, it is a possibility that the virtual non-bank status of cannabis products will be replicated for hemp products.

• Insurance and Recalls: Product liability carriers and general liability markets will reassess coverage for intoxicating hemp. Retailers may demand enhanced certifications or pull products to reduce exposure.

• Enforcement Channels: While the law sets the federal baseline, state regulators, attorneys general, and local health departments often drive the first waves of action via seizures, embargoes, and consumer protection claims. Civil litigation typically follows.

None of this requires a DEA raid for pain to show up. Risks will creep in through shipping refusals, payment disruptions, insurance exclusions, and retailer pivots — well ahead of any headline enforcement.

Winners, Losers, and the Mess in Between

Regulated marijuana operators and large alcohol interests have largely pushed for this outcome, citing safety and fairness. They’re poised to benefit as intoxicating hemp exits mass retail and e-commerce. Meanwhile, hemp businesses — from boutique manufacturers to national beverage brands — face the loss of a high-growth category and the prospect of costly reformulation or wind-downs. Some states will try to preserve parts of the market others will align quickly with the federal shift. Litigation is likely, but businesses should not bank on a court rescue or state bailout.

Timeline and Transition: Short, Uneven, and Risky

The one-year grace period is not a free pass. Market infrastructure is already repositioning. Inventory built today may be unsellable tomorrow, and the closer we get to the effective date, the harder it will be to move stock, insure shipments, or secure merchant services. Expect uneven state responses and evolving FDA signals that may broaden the set of “THC-like” cannabinoids on the chopping block.

What Businesses Should Do Now

Start with a sober, SKU-by-SKU reality check.

• Map your portfolio against “total THC” and the “naturally occurring” test.

• Identify any products that depend on CBD-to-THC conversions or contain cannabinoids with arguable “similar effects.”

• Stress-test your supply chain: carriers, payment processors, insurers, and key retail partners.

• Develop a plan for product reformulation, substitution, or wind-down, including contracts that may need amendment and inventory that may need reclassification, return, or destruction.

• Monitor state-level moves and FDA positioning closely — both could accelerate practical constraints ahead of the federal effective date.

The Bottom Line

Congress just slammed the door on intoxicating hemp as a national consumer category. By redefining hemp to include total THC and sidelining non-naturally occurring intoxicants, the law removes the legal scaffolding that propped up delta-8, THCA flower, and similar products. The enforcement clock is ticking, but the market clock is ticking faster. If intoxicating hemp is part of your business model, treat the next year as a de-risking sprint — not a waiting period.

ArentFox Schiff’s Cannabis Industry team regularly partners with clients to anticipate changes, identify potential issues early, and craft strategic, tailored solutions that help navigate the intricate web of regulations unique to the cannabis sector. For more information, contact one of the authors, a member of our Cannabis team, or the AFS attorney with whom you normally work.